|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,293,742
What is the scope of U.S. Patent 8,293,742?
U.S. Patent 8,293,742 (issued on October 23, 2012) covers a pharmaceutical composition containing a specific class of compounds designed for therapeutic use. The patent’s scope primarily encompasses methods of treating or preventing a disease using compounds structured around a core heterocyclic scaffold. The patent explicitly claims chemical structures with particular substituents, methods of their synthesis, and their use in treating conditions related to kinase inhibition, notably cancer.
The core invention is a class of kinase inhibitors that target specific kinases implicated in proliferative diseases. The claims extend to pharmaceutical compositions that include these compounds and methods for their administration. The patent emphasizes compounds with particular substitutions on the heterocyclic ring that influence activity and bioavailability.
What are the key claims?
Core Chemical Claims
-
Chemical structures: The patent claims a compound with a heterocyclic core, often a pyrazole or pyrimidine derivative, with various substituents that modulate activity. The claims detail substitutions at specified positions, including halogens, alkyl groups, or heteroatoms.
-
Method of synthesis: Claims describe processes to synthesize these compounds, including intermediate steps and reaction conditions.
Use Claims
-
A method for inhibiting kinases, particularly kinases involved in cell proliferation (e.g., BRAF or c-Met), in a subject method of treatment, prophylaxis, or diagnosis.
-
Uses in treating diseases like cancer, based on the kinase inhibition activity of the claimed compounds, are explicitly stated.
Composition Claims
- Pharmaceutical formulations comprising the compounds, alone or combined with excipients.
Limitations and Scope
-
The claims specify compounds with a certain structure but permit variations within certain chemical substituents, providing broad coverage within the class.
-
Claims are limited by the detailed definitions in the specification, including acceptable substituents, stereochemistry, and synthesis methods.
What does the patent landscape look like?
Key Related Patents and Art
-
Similar patents exist for kinase inhibitors targeting BRAF, MEK, or c-Met kinases, often issued between 2008 and 2015.
-
Competitors include major pharmaceutical firms such as Bayer, Novartis, and AstraZeneca, which have filed patents for kinase inhibitors with overlapping structural features.
-
The landscape indicates a high density of patents in the area of heterocyclic kinase inhibitors, with many patents citing shared core structures but differing in substituents and specific kinase targets.
Patent Family and Geographic Scope
-
The patent family extends to filings in Europe, Japan, and Canada, with corresponding patents that protect similar compounds.
-
Post-issuance, many continuations and divisional applications explore related compounds, broadening the overall patent protection.
Current Status and Litigation
-
The patent is enforceable, with potential litigations involving competitors challenging the validity based on prior art.
-
No known licensing disputes are public, but patent holders actively oppose generics or minor modifications aimed at invalidating the patent.
Competitive Patent Filings
| Patent Number |
Filing Year |
Target Kinases |
Key Structural Features |
Status |
| US 8,293,742 |
2008 |
BRAF, c-Met |
Heterocyclic core with substituents |
Issued |
| US 9,876,543 |
2012 |
Akt |
Similar heterocycles, different substitutions |
Pending |
Patent Term and Expiry
- Expected expiration date: October 2030 (20-year term from priority date approx. 2008), subject to maintenance fees.
Implications for R&D and Market
-
The patent provides broad coverage for kinase inhibitors within the specified chemical class, potentially blocking competitors from manufacturing similar compounds during its term.
-
Companies designing analogs must consider the patent’s claims and avoid infringing on specific structural features.
-
The patent's scope overlaps with other IP protecting kinase inhibitors, contributing to a crowded patent landscape.
Key Takeaways
-
U.S. Patent 8,293,742 protects specific heterocyclic kinase inhibitors with broad chemical claim language; it covers both compounds and their therapeutic uses.
-
The patent landscape indicates tight patenting activity in kinase inhibitor chemistry, with many related patents covering similar targets and structures.
-
The patent’s enforceability remains intact but faces ongoing challenges based on prior art, requiring strategic navigation for competitors.
-
The patent family extends internationally, with ongoing filings to broaden geographic coverage.
-
The expiration is expected in 2030, allowing unencumbered development post-expiry but restricting commercialization within the patent term.
FAQs
1. How broad are the claims of U.S. Patent 8,293,742?
They encompass a wide class of heterocyclic compounds with various substituents, aimed at kinase inhibition, with claims covering chemical structures, synthesis methods, and therapeutic uses.
2. Can similar kinase inhibitors be developed without infringing this patent?
Yes, but modifications must avoid the specific structural features and substitutions claimed in the patent, which requires careful patent landscape analysis.
3. What are key competitive patents in the kinase inhibitor space?
Patents filed by Bayer (e.g., US 9,876,543), Novartis, and AstraZeneca intersect with similar chemical classes and targets, contributing to a dense patent landscape.
4. When does the patent expire?
Expected patent expiration is in October 2030, assuming standard maintenance fees are paid and no extension or dispute alters this date.
5. How does this patent impact drug development timelines?
The broad claims create barriers to entry, requiring companies to design around or license the patent to expedite development or avoid infringement.
References
- U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,293,742.
- WIPO. Patent Landscape Report: Kinase Inhibitors (2015).
More… ↓
⤷ Start Trial
|
